CLINCAL TRIAL NEWS
Updates to Ongoing Diagnostic PET Scan Trials
Rio Pharmaceuticals in collaboration with our clinical partners is recruiting for the following diagnostic imaging clinical trials to evaluate the EAAT2 glutamate PET tracer. If you’re interested in participating in these trials and/or desire more information about recent developments of this technology please contact Rio Pharmaceuticals at the link below.
Rio is evaluating RP115 in healthy control and Alzheimer’s patients at the University of California, San Francisco (ClinicalTrials.gov ID: 
NCT05374278) as sponsored by the Alzheimer’s Drug Discovery Foundation and the National Institutes of Health, National institute on Aging (NIA). The EAAT2 PET imaging data will be correlated to other CNS PET imaging data (amyloid-beta and tau) and scored clinical observables. The initial clinical trial readout is slated during the coming year.
Rio is evaluating RP115 in a clinical study of healthy control and ALS patients in collaboration with the Herston Imaging Research Facility at the University of Queensland, Australia. The ALS clinical study is sponsored by the US Department of Defense. The EAAT2 PET imaging data will be correlated to other CNS PET imaging data (18F-FDG, magnetic resonance, MR, scans) and scored clinical observables. The initial clinical trial readout is anticipated during the coming year.
